Gigagen, Inc.

Gigamune, Inc.

Other

Adam Shultz Adler

David Scott Johnson

Rena Aviva Mizrahi

Matthew James Spindler

Yoong Wearn Lim

Michael Asensio

Kacy Stadtmiller

Sheila Keating

Angelica V Medina-Cucurella

Ariel Niedecken

Emily Benzie

Steven A Rosenberg

Drew M Pardoll

Suzanne L Topalian

Elizabeth A Jaffee

Ellen Wagner

Ayla Lynn Nelson

Erica Lyn Stone

Scott Johnson David

Lyn Stone Erica

Aviva Mizrahi Rena

Wearn Lim Yoong

Provided herein are antigen-binding proteins (ABPs) that selectively bind to CTLA-4 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.

Anti-CTLA-4 binding proteins and methods of use thereof

Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.

Recombinant polyclonal proteins targeting COVID-19 and methods of use thereof

Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.

Recombinant fusion proteins and libraries from immune cell repertoires

Provided herein are methods that enable parallel evaluation of multiple functional nucleic acids in individual cells or subpopulations of cells, in the context of incubation with other types of single cells. The key insight is concurrent measurement of polynucleic acids derived from small populations of at least two different cell types, such that function in one cell type is linked to the clonal identity of another cell. These methods simultaneously process thousands, millions, or more single cells or small populations of cells. The method integrates molecular, algorithmic, and engineering approaches. This invention has broad and useful application in a number of biological and medical fields, including immunology and drug discovery.

Systems and methods for massively parallel combinatorial analysis of single cells

Provided herein are compositions comprising recombinant polyclonal protein (RPP) derived from mammalian plasma cells and plasmablasts. Specifically, RPPs specific to Zika virus are provided. Also provided are the methods of using the RPP for treatment of viral infection and the methods of making the RPPs.

Recombinant polyclonal proteins targeting Zika and methods of use thereof

Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell rectors with specificity against EBV or CMV peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against viral infections.

Engineered cells expressing anti-viral T cell receptors and methods of use thereof

Growing community of inventors

Belmont, CA, United States of America

Adam Shultz Adler